

PeptiDream Awarded Prime Status in ISS ESG Corporate Rating for the First Time

KANAGAWA, JAPAN – February 10, 2025 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587) today announced that PeptiDream has received Prime status* in ISS ESG Corporate Rating** for the first time. ISS ESG is a leading ESG rating agency, and the responsible investment arm of US proxy advisory firm, Institutional Shareholder Services Inc, (ISS).



The ESG Corporate Rating evaluates the initiatives of more than 8,100 companies globally under its three pillars-ESG (Environmental, Social, and Governance), and awards Prime status as an ESG leader to companies that have received high evaluations in their respective industries.

Through continuous efforts to fulfill the Group's mission of "discovering the next-generation of transformational medicines that will drastically improve the lives of patients worldwide," the PeptiDream Group will continue to promote sustainability while enhancing information disclosure and communication with our stakeholders.

For information including the Company's initiatives relating to sustainability, please see the link below.

<https://www.peptidream.com/en/sustainability/effort/>

*As of December 9, 2024

**ESG Corporate Rating : <https://www.issgovernance.com/esg/ratings/>

About PeptiDream Inc.

PeptiDream Inc. (Tokyo Stock Exchange Prime Section 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en/

Inquiries:**PeptiDream Inc.**

Contact: Yuko Okimoto, IR & Public Affairs

Email: info@peptidream.com